Skip Navigation and Go To Content

保护人类受试者委员会

IRB的历史

The recognition of the need forguidelinesdealing with human subjects in research emerged following theNurembergtrials, where the medical experimentation abuses of World War II Nazi doctors came to public attention. This led to the creation of the Nuremberg Code in 1945, the first legal attempt to deal with ethical issues of modern research. As biomedical research efforts expanded the international need for a more specific code of ethics was formulated in the 1964 Declaration of Helsinki.

In the United States, by 1953 the National Institutes of Health required that all proposed clinical research projects at its center in Bethesda obtain approval from a protection of human subjects review panel. In 1966, the United States Public Health Service issued its first set of regulations extending this review requirement to all "extramural" research supported by the agency. These rules were further revised in 1971 and 1974 and led to the establishment of institutional review boards (IRBs) at hundreds of institutions receiving federal funding for research.

During this period revelations of human subjects’ abuse in the U.S. culminated in the 1972 public disclosure of the 30-year government supported Tuskegee Syphilis Study, in which 300 black rural men were left untreated for diagnosed syphilis after effective antibiotics became available. This prompted Public Law 93-348 calling for the establishment of the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. In 1979 the Commission published recommendations, known as the Belmont Report, which served as the basis for revised federal regulations published in the Federal Register in 1979 and subsequently revised several times resulting in the current Code of Federal Regulations Title 45-Part 46 Protection of Human Subjects (45 CFR 46) effective as of 1991.

贝尔蒙特报告建立了三个一般的道德原则,这些原则继续应用于人类受试者的研究:beplay苹果手机能用吗

  • Beneficence:为了最大程度地利用科学,人类和研究参与者的利益,并避免或最大程度地减少风险或伤害。beplay苹果手机能用吗
  • 尊重:To protect the autonomy and privacy rights of participants.
  • Justice:To ensure the fair distribution among persons and groups of the costs and benefits of research.

To view MISSION OF UT-IRB


CPHS HELPLINE 713-500-7943
Iris热线索林713-500-7960
UTHealth’s Compliance Hotline (1-888-472-9868)

我们如何改善此网站?


保护人类受试者委员会
6410范宁,套房1100
德克萨斯州休斯顿77030

Phone 713-500-7943
传真713-500-7951
Emailcphs@uth.tmc.edu

IRIS Support713-500-7960

aahrpp logo

CLINICAL TRIALS RESOURCE CENTEROFFICE OF RESEARCH环境健康与安全

CORE LABORATORIES赞助项目技术管理

Baidu